Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of gemcitabine added to paclitaxel-containing epirubicin-based adjuvant chemotherapy in early breast cancer
ISRCTN51146252Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2001
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, paclitaxel, epirubicin and cyclophosphamide in breast cancer (2 arms), sponsored by University of Birmingham. Primary endpoint: Five-year disease-free survival. Started Aug 2001; status: completed.
02
Drugs
gemcitabinepaclitaxelepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN51146252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51146252.